Your browser doesn't support javascript.
loading
Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial.
Grundy, Scott M; Vega, Gloria Lena; McGovern, Mark E; Tulloch, Brian R; Kendall, David M; Fitz-Patrick, David; Ganda, Om P; Rosenson, Robert S; Buse, John B; Robertson, David D; Sheehan, John P.
Affiliation
  • Grundy SM; The University of Texas Southwestern Medical Center, Room Y3206, 5323 Harry Hines Blvd, Dallas, TX 75390-9052.
Arch Intern Med ; 162(14): 1568-76, 2002 Jul 22.
Article in En | MEDLINE | ID: mdl-12123399
Subject(s)
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / Hyperlipidemias / Hypolipidemic Agents / Niacin Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: America do norte Language: En Journal: Arch Intern Med Year: 2002 Document type: Article
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / Hyperlipidemias / Hypolipidemic Agents / Niacin Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: America do norte Language: En Journal: Arch Intern Med Year: 2002 Document type: Article